Pratteln, Switzerland, November 25, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 937,928 treasury shares. The number of shares recorded in the commercial register has been increased to 18,983,321 shares.
On November 24, 2020, 937,928 shares were issued out of the existing authorized capital as treasury shares. Santhera expects to use these shares for purposes of its financing arrangements. The new shares will be listed as per November 25, 2020.
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera has an exclusive license for all indications worldwide to vamorolone, a first-in-class dissociative steroid with novel mode of action, currently investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases, as well as an exploratory gene therapy approach targeting congenital muscular dystrophies. Santhera out-licensed ex-North American rights to its first approved product, Raxone® (idebenone), for the treatment of Leber’s hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit www.santhera.com.
Raxone® is a trademark of Santhera Pharmaceuticals.
For further information please contact:
public-relations@santhera.com or
Eva Kalias, Head External Communications
Phone: +41 79 875 27 80
eva.kalias@santhera.com
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
# # #
Attachment
GALWAY, Ireland, June 11, 2025 /PRNewswire/ -- TE Connectivity plc (NYSE: TEL) announced today that…
BROOKFIELD, Wis., June 11, 2025 /PRNewswire/ -- SRM Equity Partners ("SRM"), an operationally focused private…
MSD Solutions Lab programs unite academic researchers and industry partners to drive innovation WASHINGTON, June…
Darby 3.0 automates patient intake workflows from fax to EMR, helping HME providers scale without…
Empowering researchers at every level to test hypotheses, validate findings, and collaborate to advance science…
— One of 65 startups chosen from nearly 1,500 global applicants — — Selected to…